Bristol Myers Squibb Company may have entered a new era under new CEO Christopher Boerner, who took the helm from retiring CEO Giovanni Caforio in November – an era in which the company more aggressively looks to fill gaps in its portfolio through mergers and acquisitions. Bristol announced on 26 December that it would pay $4.1bn for RayzeBio, Inc., just four days after BMS said it would buy Karuna Therapeutics, Inc. for $14bn.
BMS Makes Second Big Buy Of December, Pays $4.1bn For RayzeBio
Bristol Myers Squibb makes its entrance into the increasingly competitive space of radiopharmaceuticals with its latest purchase, just days after its $14bn Karuna buy.
More from Deals
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.